-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Cerebral amyloid vessel characteristics disease (CAA) is amyloid β (Aβ) deposition of basement membrane lining the arteries and capillaries and small arteries, may be due to impaired clearance of A [beta]
.
As a result, the blood vessel wall becomes weak, resulting in impaired integrity of the blood-brain barrier (BBB), and blood extravasates to the parenchyma in the form of lobar microbleeds (CMBs) and intracerebral hemorrhages (ICHs)
.
At present, the diagnosis of CAA in life is based on the revised Boston standard, using magnetic resonance imaging (MRI) to mark the hemorrhagic manifestations of CAA
diagnosis
Cerebrospinal fluid (CSF) markers may provide an opportunity to identify CAA at an early stage, and may allow this biomarker to be used to monitor the progress of cerebrovascular Aβ pathology
.
CSF platelet-derived growth factor receptor-β (PDGFRβ) is a potential biomarker of CAA
In addition, in patients with mild cognitive impairment (MCI), using dynamic contrast-enhanced MRI (DCE-MRI), the increase in PDGFRβ levels in CSF is related to the increase in BBB permeability
.
In addition, the concentration of CSF PDGFRβ increased in MCI patients (defined as a clinical dementia score [CDR] of 0.
5), and increased to a higher level in dementia patients (CDR of 1.
0)
.
In addition, among participants with AD+ biomarkers (defined as CSF Aβ42, phosphorylated tau[p-tau], and total tau[t-tau] levels are abnormal; cognitive status is unknown), compared with no such biomarkers Compared with the control group, the level of CSFPDGFRβ increased
.
With this, Anna de Kort and others of Radboudumc University Medical Center (Radboudumc) in the Netherlands explored:
(1) Whether the CSF PDGFRβ level of CAA patients is higher than that of the control group;
(2) Verify the previously described results: only in patients with memoryless MCI (aMCI) (CDR 0.
5), AD patients with mild dementia (CDR 1.
0) and AD patients with moderate dementia (CDR 2.
0)
(3) Compared with the control group without such characteristics, verify the CSF PDGFRβ level of aMCI/AD patients with AD+ biomarker characteristics
They by enzyme-linked immunoassay quantitative analysis adsorption patient, aMCI / AD patients as well as CSF PDGFRβ level matched control group of CAA
.
In aMCI/AD, they assessed CSF PDGFRβ by clinical phenotype and using the AT(N) biomarker classification system defined by CSF amyloid (A), tau (T) and neurodegeneration (N) biomarkers
.
They found that: PDGFRβ levels were similar in CAA patients and the control group (P = .
78), and similar in the clinical phenotype of aMCI/AD and the control group (P = .
PDGFRβ levels were similar in CAA patients and the control group (P = .
The results of this study indicate that PDGFRβ levels are related to the characteristics of AD+ biomarkers , but are not suitable biomarkers for CAA or aMCI/AD clinical syndromes
.
Original source:
De Kort AM, Kuiperij HB, Kersten I, et al.
Normal cerebrospinal fluid concentrations of PDGFRβ in patients with cerebral amyloid angiopathy and Alzheimer's disease .
Normal cerebrospinal fluid concentrations of PDGFRβ in patients with cerebral amyloid angiopathy and Alzheimer's disease in this message
